EPRX.TO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector...

Stats
Dagens volum	15 050.00
Gjennomsnittsvolum	68 096.00
Markedsverdi	132.87M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.19
ATR14	$0.0180 (0.48%)

Eupraxia Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
TCL-A.TO	0.937
CFP.TO	0.902
AQN.TO	0.902
AW-UN.TO	0.901
BLX.TO	0.894
TULB.TO	0.893
WTE.TO	0.893
ESGF.TO	0.89
NPI.TO	0.89
BIP-UN.TO	0.889

10 Mest negative korrelasjoner
SUSA.TO	-0.93
IAF-PI.TO	-0.883
OBE.TO	-0.88
MEG.TO	-0.875
PEY.TO	-0.87
CTZ.V	-0.869
PKI.TO	-0.861
RQK.TO	-0.85
URB.TO	-0.843
VLE.TO	-0.842

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Eupraxia Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2023
Omsetning:	$0
Bruttogevinst:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2022
Omsetning:	$0
Bruttogevinst:	$-193 273 (0.00 %)
EPS:	$-1.210

Financial Reports:

No articles found.

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.